论文部分内容阅读
背景:优化人源细胞安全、有效的标记参数及细胞移植后的定位是评价其治疗效果至关重要的环节。目的:比较核磁影像对比剂超顺磁性氧化铁纳米粒子体外标记人骨髓和脐带间充质干细胞的细胞活率、标记效率及核磁共振T2*WI成像的效果,优化标记细胞处理细节。方法:培养第3代人骨髓和脐带间充质干细胞,以5-30mg/L菲立磁(FeridexⅣ)结合硫酸鱼精蛋白标记细胞。结果与结论:人骨髓和脐带间充质干细胞标记前后细胞的存活率接近(P>0.05)。以5-30mg/L菲立磁标记骨髓间充质干细胞的阳性标记率差异无显著性意义(P>0.05);而5mg/L菲立磁标记脐带间充质干细胞的阳性标记率与20和30mg/L菲立磁标记的差异有显著性意义(P<0.05);10mg/L菲立磁标记脐带间充质干细胞的阳性标记率低于骨髓间充质干细胞(P<0.05)。当≥20mg/L菲立磁标记细胞时,2种来源的细胞悬液中均出现不易洗脱和过滤去除的氧化铁颗粒。标记后细胞在3.0TMRGRET2*WI扫描均见随菲立磁的浓度升高,信号强度减弱。提示这2种组织来源的间充质干细胞,以10mg/L的菲立磁-硫酸鱼精蛋白复合物标记是安全有效的,可用临床T2*WI的MR成像观察。
Background: Optimizing human cell safety, effective labeling parameters, and positioning after cell transplantation are crucial components in assessing the efficacy of the treatment. OBJECTIVE: To compare the cell viability, labeling efficiency and T2 ~ WI imaging of human bone marrow and umbilical cord mesenchymal stem cells labeled with contrast magnetic nanoparticles contrast agent superparamagnetic iron oxide nanoparticles in vitro, and to optimize the labeling of cell processing details. Methods: The 3rd generation human bone marrow and umbilical cord mesenchymal stem cells were cultured and labeled with 5-30mg / L FeridexIV and protamine sulfate. RESULTS AND CONCLUSION: The survival rates of human bone marrow and umbilical cord mesenchymal stem cells before and after labeling were similar (P> 0.05). There was no significant difference in the positive labeling rate of 5- MSCs with 5-30 mg / L phenanthrene-labeled MSCs (P> 0.05), while the positive labeling rate of 5 mg / (P <0.05). The positive labeling rate of 10 mg / L filule labeled umbilical cord mesenchymal stem cells was lower than that of bone marrow mesenchymal stem cells (P <0.05). When ≥ 20mg / L Philippus magnetic labeled cells, the two kinds of sources of cell suspension are not easy to elute and filter to remove the iron oxide particles. After labeling, the cells in 3.0TMRGRET2 * WI scan were seen with the concentration of phenanthrene increased, the signal intensity weakened. These two tissue-derived mesenchymal stem cells suggest that labeling with 10 mg / L of pheniridine-protamine sulfate complex is safe and effective and can be observed with MR imaging of clinical T2 * WI.